Hospital.med.saga-u.ac.jp

Akiyama T, Mizuta T, Kawazoe S, Eguchi Y, Kawaguchi Y, Takahashi H, Ozaki I, Fujimoto K. , 2011: Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients. World J Gas- Eguchi Y, Mizuta T, Sumida Y, Ishibashi E, Kitajima Y, Isoda H, Horie H, Tashiro T, Iwamoto E, Takahashi H, Kwashiorkor T, Soejima S, Kawaguchi Y, Oda Y, Emura S, Iwakiri R, Ozaki I, Euchar T, Ono N, Anza K, Fu- jimoto K, Koizumi S: The pathological role of visceral fat accumulation in steatosis, inflammation, and pro- gression of nonalcoholic fatty liver disease. J Gastroenterol 46 (Suppl. 1): 70-78, 2011.
Eguchi Y, Mizuta T, Sumida Y, Kitajima Y, Fujimoto K, Koizumi S: Reply to the letter by L. Filik regarding “Visceral and subcutaneous fat accumulation and nonalcoholic fatty liver disease”. J Gastroenterol 46: 418, Fujimoto K, Hongo M: Safety and efficacy of long term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with reflux esophagitis. Intern Med 50: 179-188, 2011.
Fujimoto K: Reply to the letter regarding “long-term maintenance therapy with rabeprazole for reflux esoph- Kakimoto T, Shiraishi R, Iwakiri R, Fujimoto K, Takahashi H, Hamajima H, Mizuta T, Ideguchi H, Toda S, Kitajima Y, Ozaki I, Matsuhashi S: Expression patterns of the tumor suppressor PDCD 4 and correlation with β-catenin expression in gastric cancers. Oncology Reports 26: 1385-1392, 2011.
Kobayashi Y, Kawaguchi Y, Mizuta T, Kwashiorkor T, Ode S, Ooze N, Takahashi H, Inane S, Euchar Y, Anza K, Ozaki I, Fujimoto K: Metabolic factors are associated with serum alanine aminotransferase levels in pa- tients with chronic hepatitis C. J Gastroenterol 46: 529-535, 2011.
Miao L, Shiraishi R, Fujise T, Kuroki T, Kakimoto T, Sakata Y, Takashima T, Iwakiri R, Fujimoto K, Shi R, Li X: Chemopreventive effect of mofezolac on beef tallow diet/azoxymethane-induced colon carcinogenesis in rats. Hepato-Gastroenterology 58: 81-88, 2011.
Mizuguchi M, Irie H, Nakazono T, Kamochi N, Egashira Y, Nishihara M, Shimoda R, Tsunada S, Iwakiri R, Fujimoto K, Kudo S: Aneurismal type of colorectal cancer: imaging characteristics of gastrointestinal endo- scopy, computed tomography and magnetic resonance imaging. Hepato-Gastroenterology 58: 395-399, 2011.
Nomoto N, Kojima N, Aoki S, Uchihashi K, Matsunobu A, Koike E, Ootani A, Yonemitsu N, Fujimoto K, Toda S: Interaction between adipose tissue stromal cells and gastric cancer cells in vitro. Cell Tissue Res 344: Oridate N, Totashiki R, Watanabe Y, Taguchi A, Kawamura O, Fujimoto K: Endoscopic laryngeal findings in Japanese patients with larngopharyngeal reflux symptoms. Int J Otolarngol 2012: 1-4, 2011.
Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, Eguchi Y, Suzuki Y, Imai S, Kanemasa K, Fu- jita K, Chayama K, Yasui K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Okanoue T: A simple clinical scor- ing system using ferritin, fasting insulin, and type IV collagen 7 S for predicting steatohepatitis in nonalco- holic liver disease. J Gastroentrol 46: 257-268, 2011.
Takahashi H, Mizuta T, Eguchi Y, Kawaguchi Y, Kuwashiro T, Oeda S, Isoda H, Oza N, Iwane S, Izumi K, Anzai K, Ozaki I, Fujimoto K: Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C. J Gastroenterol 46: 790-798, 2011.
Tsuruoka N, Iwakiri R, Hara M, Shirahama N, Sakata S, Eguchi Y, Shimoda R, Ogata S, Tsunada S, Sakata H, Fujimoto K: NSAIDs is a significant risk factor for colonic diverticular hemorrhage in elder patients: evalu- ation by a case-control study. J Gastroenterol Hepatol 26: 1047-1052, 2011.
Yoneda M, Fujii H, Sumida Y, Hyogo H, Itoh Y, Ono M, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Imajo K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T: Platelet count for predict- ing fibrosis in nonalcoholic fatty liver disease. J Gastroenterol 46: 1300-1306, 2011.
Fujimoto. K: Risk factors for PPI resistance GERD. APDW 2011. 2011, 10, 1-4. (Symposium).
Eguchi Y, Hyogo H, Ono M, Mizuta T, Chayama K, Saibara T, Fujimoto K. Annual: Role of dyslipidemia and hyperglycemia in the individuals with nonalcoholic fatty liver disease in the general population in Japan.
Meeting of the American Association of for the Study of Liver Diseases, DDW. 2011, 5, 7-10. Abstract: A Oeda S, Mizuta T, Isoda H, Kuwashiro T, Iwane S, Kawaguchi Y, Ozaki I, Fujimoto K: The advantage in long- term survival of radiofrequency ablation for hepatocellular carcinoma patients: historical comparison with ethanol injection. Meeting of the American Association of for the Study of Liver Diseases, DDW. 2011, 5, 7- Oridate N, Tokashiki R, Watanabe Y, Taguchi A, Kawamura O, Fujimoto K: Comparison of the laryngopa- haryngeal reflux symptoms. Annual Meeting of the American Gastroenterological Association, DDW. 2011, 5, Oshima T, Yamasaki T, Okugawa T, Toyoshima F, Tomita T, Fujimoto K, Kinoshita Y, Haruma K, Miwa H: Augmented symptoms response to acid in patients with functional dyspepsia. Annual Meeting of the Ameri- can Gastroenterological Association, DDW. 2011, 5, 7-10. Abstract: A 280.
Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Fujita K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T: Validation of the FIB 4 index in a Japanese nonalcoholic fatty liver disease population. Annual Meeting of the American Association of for the Study of Liver Diseases, DDW. 2011, 5, 7-10. Abstract: A 1297.

Source: http://www.hospital.med.saga-u.ac.jp/cancer-center/gyouseki/syoukakinaika.pdf

wheelereap.org

September 2004 Wellness, Productivity, & You! Wheeler EAP 1-800-275-3327 Your Personal T wo things must be in balance for an effective team: content and process. Content is the I f you are motivated to pursue a goal, put together your per-sonal action plan. Its purpose: to put the goal into action and make its success more likely. Successful plans are writ-team

Informativa intervento di ptk o cheratectomia fototerapeutica

SCHEDA INFORMATIVA INTERVENTO DI VITRECTOMIA PER RETINOPATIA DIABETICA Approvata dalla Società Oftalmologica Italiana - Anno 2003 Gentile Signora, Signore, Lei soffre di una patologia responsabile di un calo alla vista e di altre possibili e gravi complicanze. Questa scheda contiene le informazioni sul trattamento che Le è proposto, sui risultati e sui rischi. Tutte le espression

Copyright ©2010-2018 Medical Science